Global Blood Therapeutics, Inc.
GBT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $1,841,817 | $2,656,377 | $4,635,985 | $2,099,737 |
| - Cash | $684,717 | $494,766 | $302,237 | $275,357 |
| + Debt | $659,617 | $153,651 | $75,425 | $0 |
| Enterprise Value | $1,816,717 | $2,315,262 | $4,409,173 | $1,824,380 |
| Revenue | $194,749 | $123,803 | $2,108 | $0 |
| % Growth | 57.3% | 5,773% | – | – |
| Gross Profit | $191,433 | $121,817 | $2,060 | $0 |
| % Margin | 98.3% | 98.4% | 97.7% | – |
| EBITDA | -$278,531 | -$226,921 | -$256,834 | -$169,586 |
| % Margin | -143% | -183.3% | -12,183.8% | – |
| Net Income | -$303,091 | -$247,553 | -$266,766 | -$174,193 |
| % Margin | -155.6% | -200% | -12,654.9% | – |
| EPS Diluted | -4.82 | -4.04 | -4.57 | -3.41 |
| % Growth | -19.3% | 11.6% | -34% | – |
| Operating Cash Flow | -$256,813 | -$211,862 | -$194,417 | -$135,375 |
| Capital Expenditures | -$3,233 | -$8,754 | -$3,460 | -$4,824 |
| Free Cash Flow | -$260,046 | -$220,616 | -$197,877 | -$140,199 |